Stock listing
NASDAQ:KYTX Kyverna Therapeutics, Inc. Stock
Home listing (NASDAQ) of Kyverna Therapeutics, Inc.
Follow Kyverna Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KYTX
$4.26 USD -0.22 (-4.9%)
Close on Nov 20, 2026
- Day range
- $4.18 – $4.58 USDNov 20, 2026
- Volume
- 1.34M sharesNov 20, 2026
- Market cap
- $263.5M USDAt the close on Nov 20, 2026 · price × 61.84M shares outstanding
- 52-week range
- $4.18 – $13.67 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.55M USDMedian day 813,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KYTX · Home | $4.26 USD | -0.22 (-4.9%) | 1,338,336 | $4.30 | $4.58 | $4.175 | $4.48 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KYTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.26 | -0.22 | -4.9% | $4.30 | $4.58 | $4.175 | 1,338,336 | |
| $4.48 | -0.22 | -4.7% | $4.69 | $4.75 | $4.40 | 1,046,701 | |
| $4.70 | -0.06 | -1.3% | $4.83 | $4.83 | $4.575 | 616,413 | |
| $4.76 | -0.29 | -5.7% | $4.95 | $5.06 | $4.735 | 767,375 | |
| $5.05 | +0.02 | +0.4% | $5.275 | $5.54 | $4.82 | 834,188 | |
| $5.03 | -0.09 | -1.8% | $5.26 | $5.29 | $4.765 | 1,197,801 | |
| $5.12 | +0.04 | +0.8% | $5.12 | $5.23 | $5.018 | 504,146 | |
| $5.08 | -0.09 | -1.7% | $5.14 | $5.28 | $5.00 | 472,269 | |
| $5.17 | +0.29 | +5.9% | $4.93 | $5.24 | $4.80 | 831,395 | |
| $4.88 | +0.27 | +5.9% | $4.68 | $5.00 | $4.65 | 885,550 | |
| $4.61 | -0.55 | -10.7% | $5.11 | $5.11 | $4.495 | 1,417,216 | |
| $5.16 | 0.00 | 0.0% | $5.30 | $5.46 | $5.02 | 973,918 | |
| $5.16 | -0.06 | -1.1% | $5.28 | $5.48 | $5.12 | 703,002 | |
| $5.22 | -0.45 | -7.9% | $5.83 | $5.835 | $5.093 | 822,251 | |
| $5.67 | -0.18 | -3.1% | $5.74 | $5.87 | $5.55 | 640,116 | |
| $5.85 | -0.04 | -0.7% | $5.91 | $6.12 | $5.835 | 844,506 | |
| $5.89 | +0.26 | +4.6% | $5.58 | $5.935 | $5.56 | 995,061 | |
| $5.63 | +0.36 | +6.8% | $5.24 | $5.67 | $5.16 | 916,565 | |
| $5.27 | -0.12 | -2.2% | $5.35 | $5.40 | $5.18 | 809,993 | |
| $5.39 | -0.34 | -5.9% | $5.68 | $5.68 | $5.36 | 827,200 | |
| $5.73 | -0.11 | -1.9% | $5.825 | $5.985 | $5.67 | 519,400 | |
| $5.84 | -0.20 | -3.3% | $6.15 | $6.30 | $5.80 | 829,200 | |
| $6.04 | +0.21 | +3.6% | $5.83 | $6.20 | $5.80 | 766,300 | |
| $5.83 | +0.16 | +2.8% | $5.71 | $5.94 | $5.67 | 837,500 | |
| $5.67 | -0.30 | -5.0% | $5.94 | $6.05 | $5.64 | 724,500 | |
| $5.97 | +0.285 | +5.0% | $5.67 | $6.02 | $5.67 | 779,400 | |
| $5.685 | -0.085 | -1.5% | $5.76 | $5.845 | $5.61 | 1,275,700 | |
| $5.77 | -0.44 | -7.1% | $6.17 | $6.17 | $5.755 | 1,241,500 | |
| $6.21 | -0.18 | -2.8% | $6.34 | $6.46 | $6.19 | 417,100 | |
| $6.39 | +0.21 | +3.4% | $6.20 | $6.58 | $6.175 | 876,400 | |
| $6.18 | +0.01 | +0.2% | $6.06 | $6.216 | $5.96 | 1,317,000 | |
| $6.17 | +0.01 | +0.2% | $6.12 | $6.31 | $6.02 | 650,300 | |
| $6.16 | -0.16 | -2.5% | $6.38 | $6.45 | $6.13 | 739,400 | |
| $6.32 | +0.10 | +1.6% | $6.30 | $6.435 | $6.00 | 813,500 | |
| $6.22 | -0.30 | -4.6% | $6.62 | $6.754 | $6.17 | 1,180,600 | |
| $6.52 | -0.28 | -4.1% | $6.80 | $6.91 | $6.51 | 787,500 | |
| $6.80 | -0.04 | -0.6% | $6.875 | $7.10 | $6.73 | 746,200 | |
| $6.84 | +0.02 | +0.3% | $6.83 | $6.95 | $6.75 | 826,300 | |
| $6.82 | +0.01 | +0.1% | $6.72 | $6.95 | $6.65 | 997,000 | |
| $6.81 | -0.18 | -2.6% | $6.99 | $7.015 | $6.62 | 1,502,400 | |
| $6.99 | -0.08 | -1.1% | $7.80 | $7.92 | $6.675 | 3,275,100 | |
| $7.07 | -0.44 | -5.9% | $7.50 | $7.54 | $6.99 | 1,032,200 | |
| $7.51 | +0.39 | +5.5% | $7.18 | $7.59 | $7.11 | 836,500 | |
| $7.12 | -0.01 | -0.1% | $7.25 | $7.26 | $6.99 | 678,500 | |
| $7.13 | +0.09 | +1.3% | $7.02 | $7.19 | $7.00 | 960,600 | |
| $7.04 | +0.14 | +2.0% | $7.11 | $7.18 | $6.96 | 530,800 | |
| $6.90 | -0.06 | -0.9% | $7.02 | $7.155 | $6.855 | 685,700 | |
| $6.96 | -0.44 | -5.9% | $7.34 | $7.34 | $6.87 | 1,070,900 | |
| $7.40 | +0.14 | +1.9% | $7.25 | $7.49 | $7.21 | 533,900 | |
| $7.26 | -0.09 | -1.2% | $7.47 | $7.59 | $7.205 | 751,500 | |
| $7.35 | -0.29 | -3.8% | $7.51 | $7.53 | $7.34 | 854,400 | |
| $7.64 | -0.43 | -5.3% | $8.00 | $8.165 | $7.595 | 918,200 | |
| $8.07 | -0.18 | -2.2% | $8.17 | $8.21 | $7.97 | 586,200 | |
| $8.25 | -0.10 | -1.2% | $8.26 | $8.38 | $8.20 | 500,800 | |
| $8.35 | -0.265 | -3.1% | $8.71 | $8.78 | $8.28 | 595,300 | |
| $8.615 | +0.265 | +3.2% | $8.37 | $8.72 | $8.24 | 599,900 | |
| $8.35 | -0.125 | -1.5% | $8.27 | $8.42 | $7.60 | 1,782,300 | |
| $8.475 | +0.105 | +1.3% | $8.33 | $8.52 | $8.14 | 484,000 | |
| $8.37 | -0.27 | -3.1% | $8.52 | $8.55 | $8.31 | 524,900 | |
| $8.64 | +0.03 | +0.3% | $8.58 | $8.787 | $8.45 | 432,400 | |
| $8.61 | -0.23 | -2.6% | $8.81 | $8.839 | $8.504 | 413,800 | |
| $8.84 | +0.60 | +7.3% | $8.36 | $8.885 | $8.265 | 778,000 | |
| $8.24 | -0.18 | -2.1% | $8.32 | $8.40 | $8.00 | 565,100 | |
| $8.42 | +0.29 | +3.6% | $8.24 | $8.58 | $8.19 | 663,600 | |
| $8.13 | -0.74 | -8.3% | $8.73 | $8.76 | $8.11 | 953,900 |
- Ticker
- NASDAQ:KYTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 37 slides
Latest news
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
Nov 12, 2026
Closed $5.03 (-1.8%) on Nov 12, 2026
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
Nov 9, 2026
Closed $5.17 (+5.9%) on Nov 9, 2026
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 5, 2026
Closed $4.88 (+5.9%) on Nov 6, 2026
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Oct 23, 2026
Closed $5.39 (-5.9%) on Oct 23, 2026
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Oct 21, 2026
Closed $5.84 (-3.3%) on Oct 21, 2026
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Oct 7, 2026
Closed $6.17 (+0.2%) on Oct 7, 2026
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Sep 24, 2026
Closed $6.99 (-1.1%) on Sep 24, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Sep 2, 2026
Closed $8.35 (-3.1%) on Sep 3, 2026
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Aug 11, 2026
Closed $8.05 (+0.4%) on Aug 12, 2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Jul 27, 2026
Closed $7.92 (+6.9%) on Jul 27, 2026
Kyverna Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 69 in all · newest Nov 12, 2026 · oldest 2024
- Decks
- 11 decks · latest October 2026
Where Kyverna Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KYTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KYTX | BOATS | United States | USD |
Valuation
Price/book 2.0× against a median of 2.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $117.8M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 2.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.1M | US$182.5M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Agenus Inc. · NASDAQ:AGEN | US$270.1M | US$218.3M | 9.2× | 1.6× | 4.0× | n/a | 22.0% | n/a | 1.80 |
| AgomAb Therapeutics NV · NASDAQ:AGMB | US$268.4M | −US$6.88M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.29 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.4M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| Median of the others | US$259.7M | US$154.4M | 9.2× | 37.3× | 4.0× | 2.0× | −112.6% | 0.1× | 1.48 |
Forecasts
4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.71 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Warner Biddle | Chief Executive Officer |
| Greg Martini | Chief Financial Officer |
| Ritesh Srivastava | Chief Legal and Compliance Officer |
| Anneliese Jameson | Senior Vice President, Clinical and Development Operations |
| Dena Grayson | Senior Vice President, Clinical Development and Medical Affairs |
| H. Talia Zhang | Senior Vice President, Global Safety, Pharmacovigilance, and Benefit-Risk |
| Tracy Rossin | Senior Vice President, Corporate Affairs |
| Christi Shaw | Executive Chairperson |
| Dan Maziasz | Chief Business Officer |
| Manal Morsy | Chief Regulatory Officer |
| Mayo Pujols | Chief Technology Officer |
| Nadia Dac | Chief Commercial Officer |
| Naji Gehchan | Chief Medical and Development Officer |
Board
| Director | Role |
|---|---|
| Christi Shaw | Executive Chairperson |
| Andrew Miller | Independent Director |
| Beth Seidenberg | Independent Director |
| Fred Cohen | Independent Director |
| Ian Clark | Independent Director |
| Mert Aktar | Independent Director |
| Sravan K. Emany | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −1.8% |
| Q2 2026 | Aug 11, 2026 · After close | +0.4% |
| Q1 2026 | May 13, 2026 | +5.0% |
| Q4 2025 | Mar 26, 2026 · After close | −2.9% |
| Q3 2025 | Nov 12, 2025 · After close | −11.6% |
| Q2 2025 | Aug 12, 2025 · After close | +14.9% |
| Q1 2025 | May 13, 2025 · After close | −7.3% |
| Q4 2024 | Mar 27, 2025 | −20.0% |
| Q3 2024 | Nov 13, 2024 · After close | −5.1% |
| Q2 2024 | Aug 12, 2024 · After close | +7.2% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +2.4% |
| Q4 2023 | Mar 26, 2024 · After close | −3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 37 slides | October 2026 |
| Corporate Update (September 2026) | Corporate update | 29 slides | Sep 24, 2026 |
| Investor Presentation (September 2026) | Investor deck | 37 slides | September 2026 |
| Jefferies Healthcare Conference 2026 | Conference | 31 slides | June 2026 |
| AAN 2026 Annual Meeting | Conference | 38 slides | Apr 22, 2026 |
| Technical Presentation (December 2025) | Technical | 30 slides | Dec 15, 2025 |
| Technical Presentation (October 2025) | Technical | 25 slides | Oct 29, 2025 |
| Investor Day (August 2025) | Investor day | 97 slides | Aug 28, 2025 |
| Investor Presentation (January 2025) | Investor deck | 29 slides | Jan 13, 2025 |
| Technical Presentation (November 2024) | Technical | 17 slides | November 2024 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (June 2024) | Investor day | 31 slides | Jun 14, 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: about US$100M · US$7.5 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Wells Fargo Securities (co-lead) | Dec 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$22.00 a share on Feb 7, 2024.
- Price
- US$22.00 a share
- Shares offered
- 14,500,000 shares of common stock
- Offering size
- US$319 million
- Underwriters' option
- Up to 2,175,000 more shares
- Underwriters
- J.P. Morgan, Morgan Stanley, Leerink Partners, Wells Fargo Securities · In the order on the cover
- Shares delivered
- On or about Feb 12, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 5, 2023 |
| Filed publicly | Jan 16, 2024 |
| Amended twice | Newest Feb 6, 2024 |
| Shares registered with an exchange | Feb 5, 2024 |
| Declared effective by the SEC | Feb 7, 2024 |
| Final prospectus, with the price | Feb 8, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 8, 2024 |
| CERT · Exchange's certificate of listing | Feb 8, 2024 |
| EFFECT · Notice that a registration is effective | Feb 7, 2024 |
| S-1/A · Registration statement, amended | Feb 6, 2024 |
| CORRESP · Letter to the SEC | Feb 5, 2024 |
| CORRESP · Letter to the SEC | Feb 5, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2024 |
| S-1/A · Registration statement, amended | Feb 1, 2024 |
| CORRESP · Letter to the SEC | Jan 25, 2024 |
| CORRESP · Letter to the SEC | Jan 16, 2024 |
All 22 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jan 16, 2024 |
| UPLOAD · Letter from the SEC | Jan 10, 2024 |
| DRS/A · Draft registration statement, amended | Jan 8, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jan 5, 2024 |
| UPLOAD · Letter from the SEC | Dec 28, 2023 |
| DRSLTR · Letter to the SEC with a draft | Dec 13, 2023 |
| DRS/A · Draft registration statement, amended | Dec 13, 2023 |
| UPLOAD · Letter from the SEC | Nov 21, 2023 |
| DRSLTR · Letter to the SEC with a draft | Nov 9, 2023 |
| DRS/A · Draft registration statement, amended | Nov 9, 2023 |
| UPLOAD · Letter from the SEC | Nov 1, 2023 |
| DRS · Draft registration statement | Oct 5, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.03M | 5.66M |
| Cost of revenue | 1.80M | 2.13M | 1.71M | 1.05M | 586.0K |
| Gross profit | -1.80M | -2.13M | -1.71M | 7.03M | 5.66M |
| Research and development | 133.7M | 112.5M | 49.9M | 28.4M | 25.9M |
| Selling, general and administrative | 36.1M | 30.1M | 12.5M | 8.01M | 6.15M |
| Operating income | -169.8M | -142.6M | -62.4M | -29.4M | -26.3M |
| Depreciation and amortization | 1.80M | 2.13M | 1.71M | 1.05M | 586.0K |
| EBITDA | -168.0M | -140.5M | -60.7M | -28.3M | -25.8M |
| Interest expense | 489.0K | 142.0K | 187.0K | 65.0K | 3.00K |
| Income before tax | -161.3M | -127.5M | -60.4M | -28.9M | -26.4M |
| Income tax | 0 | 0 | 0 | 56.0K | 1.00K |
| Net income | -161.3M | -127.5M | -60.4M | -28.9M | -26.4M |
| Earnings per share, basic | -3.64 | -3.33 | -89.61 | -0.67 | -1.02 |
| Earnings per share, diluted | -3.64 | -3.33 | -89.61 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 124.1M | 96.6M | 34.6M | 37.7M | 76.1M |
| Short-term investments | 155.2M | 189.4M | 22.9M | 13.6M | 0 |
| Current assets | 283.0M | 290.6M | 60.7M | 53.3M | 77.1M |
| Property, plant and equipment | 1.55M | 3.35M | 2.33M | ||
| Total assets | 293.8M | 304.6M | 75.2M | 66.9M | 85.5M |
| Accounts payable | 5.31M | 4.62M | 4.36M | 1.45M | 773.0K |
| Current liabilities | 36.5M | 33.8M | 19.9M | 12.0M | 15.9M |
| Long-term debt | 24.7M | ||||
| Total debt | 24.7M | 8.24M | 9.08M | 10.6M | 5.55M |
| Total liabilities | 61.5M | 38.1M | 26.0M | 140.9M | 131.7M |
| Shareholders' equity | 232.3M | 266.6M | -13.1M | -74.0M | -46.3M |
| Shares outstanding | 60.4M | 43.2M | 1.25M | 43.1M | 25.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -153.7M | -114.3M | -52.4M | -36.1M | -22.2M |
| Capital spending | -5.00K | -2.21M | -621.0K | -768.0K | -1.29M |
| Free cash flow | -153.7M | -116.5M | -53.0M | -36.9M | -23.4M |
| Cash from investing | 40.0M | -160.9M | -8.79M | -14.1M | -1.29M |
| Cash from financing | 141.2M | 337.1M | 58.1M | 11.9M | 72.5M |
| Change in cash | 27.5M | 62.0M | -3.08M | -38.3M | 49.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 19, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 27, 2026 | Material contract | SEC |
All 190 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 9, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 2, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2026 | Insider trade | SEC |
| 8-K · Current report | May 18, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 6, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 14, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 13, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 2, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 30, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| FWP · Free writing prospectus | Dec 17, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 15, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 25, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 27, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 26, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 21, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Oct 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 11, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| SC 13D · Big-stake notice | May 3, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 22, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Feb 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 8, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Feb 8, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Feb 8, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 8, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2024 | Insider trade | SEC |
| S-1/A · Registration statement, amended | Feb 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 31, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 16, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 10, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jan 5, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jan 5, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 28, 2023 | Other filings | SEC |
| SEC STAFF LETTER | Dec 15, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Dec 13, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Dec 13, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Nov 9, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Nov 9, 2023 | Offer document | SEC |
| D | Nov 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 1, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Oct 4, 2023 | Offer document | SEC |
Cap table
Built by 6ix from Kyverna Therapeutics, Inc.’s releases
- Common shares
- 61,843,444
- Fully diluted
- 61,843,444
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 61,843,444 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 61,843,444 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Beth C Seidenberg Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Sagimet Biosciences Inc. - Series A (Director · Since at least Jul 13, 2023); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past) | Director · Since at least Feb 7, 2024 |
| Beth Seidenberg Other companies: Sagimet Biosciences Inc. - Series A (Lead Independent Director · Since at least Nov 4, 2026); Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Latigo Biotherapeutics, Inc. (Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026) | Independent Director · Since at least May 29, 2026 |
| Sravan Emany Other companies: Beam Therapeutics Inc. (Chief Financial Officer · Since at least Dec 19, 2024); Assertio Holdings, Inc. (Director · Since at least Nov 14, 2023); Ironwood Pharmaceuticals, Inc. (SVP, COO and CFO · Dec 6, 2021 – Nov 18, 2024 · Past) | Independent Director · Since at least Feb 24, 2026 |
| Fred E Cohen Other companies: CareDx, Inc. (Director · Since at least Jun 12, 2026); Intellia Therapeutics, Inc. (Director · Since at least Jun 9, 2026) | Director · Since at least May 27, 2026 |
| Marc Grasso Other companies: Alector, Inc. (Chief Financial Officer · Since at least Feb 7, 2022); Kura Oncology, Inc. (CFO, CBO · Aug 21, 2018 – Jan 26, 2022 · Past) | Chief Financial Officer · Since at least Jun 30, 2025 |
| Peter Maag Other companies: CareDx, Inc. (Director · Since at least Jul 16, 2014); Miromatrix Medical Inc (Director · Jun 23, 2021 – Dec 12, 2023 · Past) | Chief Executive Officer, Director · Feb 7, 2024 – Feb 7, 2024 · Past |
| Christi Shaw Other companies: Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2026) | Executive Chairperson · Since at least Feb 24, 2026 |
| Fred Cohen Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Jun 10, 2026) | Independent Director · Since at least May 29, 2026 |
| Greg Martini Other companies: Ironwood Pharmaceuticals, Inc. (Chief Financial Officer · Since at least May 7, 2026) | Chief Financial Officer · Since at least Aug 11, 2026 |
| Gregory S Martini Other companies: Ironwood Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jan 27, 2025) | Chief Financial Officer · Since at least May 18, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Andrew Miller | Independent Director · Since at least Feb 24, 2026 |
| Anneliese Jameson | Senior Vice President, Clinical and Development Operations · Since at least Nov 4, 2026 |
| Dan Maziasz | Chief Business Officer · Since at least Mar 27, 2025 |
| Dena Grayson | Senior Vice President, Clinical Development and Medical Affairs · Since at least Nov 4, 2026 |
| H. Talia Zhang | Senior Vice President, Global Safety, Pharmacovigilance, and Benefit-Risk · Since at least Nov 4, 2026 |
| Ian Clark | Independent Director · Since at least Jan 12, 2026 |
| Manal Morsy | Chief Regulatory Officer · Since at least Nov 4, 2026 |
| Mayobanex Pujols | Chief Technology Officer · Since at least Feb 9, 2026 |
| Mayo Pujols | Chief Technology Officer · Since at least Jul 27, 2026 |
| Mert Aktar | Independent Director · Since at least Oct 21, 2024 |
| Nadia Dac | Chief Commercial Officer · Since at least Aug 11, 2026 |
| Naji Gehchan | Chief Medical and Development Officer · Since at least Oct 23, 2026 |
| Ritesh Srivastava | Chief Legal and Compliance Officer · Since at least Aug 11, 2026 |
| Ryan Alexander Jones | Chief Financial Officer · Feb 7, 2024 – Apr 11, 2025 · Past |
| Tracy Rossin | Senior Vice President, Corporate Affairs · Since at least Mar 27, 2025 |
| Warner Biddle | Chief Executive Officer · Since at least Sep 16, 2024 |
Log in to ask 6ix AI your own questions about Kyverna Therapeutics, Inc.